Drug substance	Administration route	Dose	Combinations with other drugs in the included trials
Atezolizumab (ATE)	intravenous infusion	1200 mg	ATE+BEV
Avelumab (AVE)	intravenous infusion	10 mg	AVE+AXI PEM+AXI
Axitinib (AXI)	oral administration	5 mg	AVE+AXI
Bevacizumab (BEV)	intravenous infusion	10 mg	BEV+ERL IFN+BEV TEM+BEV ATE+BEV EVE+BEV
Cabozantinib (CAB)	oral administration	60 mg	NIV+CAB
Crizotinib (CRI)	oral administration	60 mg	‐
Erlotinib (ERL)	oral administration	150 mg	BEV+ERL
Everolimus (EVE)	oral administration	5 mg or 10 mg	EVE+BEV LEN+EVE
Interferon‐alpha (IFN)	subcutaneous injection	0.5 MIU; or 3 MIU; or 6 MIU; or 9 MIU	IFN+BEV SOR+IFN NAP+IFN IFN+TEM ILN+IFN ILN+IFN+BEV
Interleukin (ILN)	subcutaneous injection	2.4 MIU	SOR+ILN ILN+IFN
Ipilimumab (IPI)	intravenous infusion	1mg	NIV+IPI
Lenvatinib (LEN)	oral administration	18 mg; or 20 mg	LEN+PEM LEN+EVE
Naptumomab (NAP)	intravenous infusion	15 mg	NAP+IFN
Nintedanib (NIN)	oral administration	200 mg	‐
Nivolumab (NIV)	intravenous infusion	3 mg or 240 mg	NIV+IPI NIV+CAB
Pazopanib (PAZ)	oral administration	800 mg	‐
Pembrolizumab (PEM)	intravenous infusion	200 mg	PEM+AXI LEN+PEM
Savolitinib (SAV)	oral administration	600 mg	‐
Sorafenib (SOR)	oral administration	400 mg	SOR+IFN SOR+ILN
Sunitinib (SUN) (main comparator in this review)	oral administration	50 mg	‐
Temsirolimus (TEM)	intravenous infusion	15 mg or 25 mg	IFN+TEM TEM+BEV
Tivozanib (TIV)	oral administration	1.5 mg	‐